Seeking Alpha

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER ...

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ...

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
Business Wire

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Disease…

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...

Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...
PharmiWeb

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS ...
WGNO

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the ...
Business Wire

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common ...
Nasdaq

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Contract Pharma

OSD Early Stage: Getting Oral Products into Clinic Early

In the fast-paced world of drug development, time is often the most precious commodity. For biotech companies working on oral ...

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...